Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hybrid Dose-fraction Radiotherapy for Metastatic Driven-genes Negative Non-small Cell Lung Cancer
NCT05348668Phase 2Completed
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- May 2022
- Primary completion
- Mar 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Progression-Free Survival at 1 year. Started May 2022; status: completed.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05348668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05348668.